• 1
    Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): II3742.
  • 2
    Talley NJ, Silverstein MD, Agreus L, et al. AGA technical review: evaluation of dyspepsia. Am Gastroenterol Assoc Gastroenterol 1998; 114: 58295.
  • 3
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 156980.
  • 4
    Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 125968.
  • 5
    Russo MW, Gaynes BN, Drossman DA. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 1999; 29: 33943.
  • 6
    Nyren O, Lindberg G, Lindstrom E. Economic costs of functional dyspepsia. Pharmacoeconomics 1992; 1: 31224.
  • 7
    Drossman D, Thompson W, Talley N, et al. Identification of subgroups of functional gastrointestinal disorders. Gastroeneterol Int 1990; 3: 15972.
  • 8
    Holtmann G, Stanghellini V, Talley NJ. Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts. Baillieres Clin Gastroenterol 1998; 12: 41733.
  • 9
    Maes BD, Ghoos YF, Hiele MI, et al. Gastric emptying rate of solids in patients with nonulcer dyspepsia. Dig Dis Sci 1997; 42: 115862.
  • 10
    Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J 1999; 318: 8337.
  • 11
    Talley N, Vakil N, Ballard E, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 110611.
  • 12
    Trimble K, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 160713.
  • 13
    Lemann M, Dedering J, Flourie B, et al. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. Dig Dis Sci 1991; 36: 124954.
  • 14
    Kanazawa M, Nomura T, Fokudo S, et al. Abnormal visceral perception in patients with functional dyspepsia: use of cerebral potentials evoked by electrical stimulation of the oesophagus. Neurogastroenterol Mot 2000; 12: 8794.
  • 15
    Mayer E & Raybould H. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 1990; 99: 27193.
  • 16
    Gershon M. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13: 1530.DOI: 10.1046/j.1365-2036.1999.00437.x
  • 17
    Moss HE & Sanger GJ. The effects of granisetron, ICS 205–930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100: 497501.
  • 18
    Prior A & Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 17580.
  • 19
    Goldberg PA, Kamm MA, Setti-Carraro P, et al. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 47883.
  • 20
    Camilleri M, Mayer E, Drossman D, et al. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5–HT3-receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114951.DOI: 10.1046/j.1365-2036.1999.00610.x
  • 21
    Camilleri MAR & Northcutt Kong S, et al. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomised placebo controlled study. Lancet 2000; 355: 103540.DOI: 10.1016/s0140-6736(00)02033-x
  • 22
    Talley N D C-J & Koch K. Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 14560.
  • 23
    Thompson W, Creed F, Drossman D, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 7591.
  • 24
    Harding JP, Hamm LR, Ehsanullah R, et al. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 10736.
  • 25
    Mantel N & Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959; 22: 71948.
  • 26
    Lehmann E. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day, 1975: 297–303.
  • 27
    Hollander M & Wolfe D. Nonparametric Statistical Methods. New York: John Wiley and Sons, Inc., 1973: 26–33.
  • 28
    Mayer EA, Naliboff B, Lee O, et al. Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 659.
  • 29
    Talley NJ, Axon A, Bytzer P, et al. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999; 13: 113548.DOI: 10.1046/j.1365-2036.1999.00584.x
  • 30
    Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 105565.DOI: 10.1046/j.1365-2036.1998.00410.x
  • 31
    Holtmann G, Goebell H, Talley NJ. Gastrointestinal sensory function in functional dyspepsia. Gastroenterology 1995; 109: 3312.
  • 32
    Klatt S, Bock W, Rentschler J, et al. Effects of tropisetron, a 5–HT3 receptor antagonist, on proximal gastric motor and sensory function in nonulcer dyspepsia. Digestion 1999; 60: 14752.
  • 33
    Zerbib F, Bruley des Varannes S, Oriola RC, et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 4037.
  • 34
    Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 5959.
  • 35
    Klein K. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 23241.
  • 36
    Veldhuyzen Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. 2): II6977.
  • 37
    Talley NJ, Shuter B, McCrudden G, et al. Lack of association between gastric emptying of solids and symptoms in nonulcer dyspepsia. J Clin Gastroenterol 1989; 11: 62530.
  • 38
    Houghton L, Foster J, Whorwell P. Alosetron, a 5-HT-3 receptor antagonist, delays colonic transit in patients with IBS and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 77582.DOI: 10.1046/j.1365-2036.2000.00762.x
  • 39
    Saslow SB, Scolapio JS, Camilleri M, et al. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut 1998; 42: 62834.
  • 40
    Laine L, Schoenfeld P, Fennerty M. Helicobacter pylori therapy is not effective for treatment of nonulcer dyspepsia: Meta-analysis of randomized controlled trials. Gastroenterology 2000; 118: a440a440.